Riskpilot← Back to searchSign inGet full accessQiagen AB
ABActiveOrg 5566725122Torshamnsgatan 35 1trWholesale of pharmaceutical and medical goods · NACE 4646Est. 200461 employees
Revenue 2024
SEK 476,6M
+8% vs 2023
EBITDA margin
4.3%
-49% vs 2023
Equity ratio
45.1%
Financial strength
Net profit 2024
SEK 1,8M
-87% vs 2023
| Revenue | SEK 476,6M | +8% |
| EBITDA | SEK 20,6M | -49% |
| Net profit | SEK 1,8M | -87% |
| Total assets | SEK 144,1M | +10% |
| Equity | SEK 65M | +3% |
| Employees | 61 | — |
Legal name
Qiagen AB
Org number
5566725122
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16 december 2004
Share capital
SEK 100 000
Employees
61 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet, direkt eller indirekt. Försäljning och distribution av molekylärbiologiska diagnostikprodukter, läkemedel, biologiska produkter och genprodukter och motsvarande verksamheter inklusive relevant mjukvara och teknisk utrustning, liksom att delta i, eller på annat sätt engagera sig i eller leda andra affärsverksamheter oavsett natur, vidare att finansiera tredje parter, ställa säkerheter, erbjuda tjänster eller ikläda sig tredje parters skyldigheter och därmed förenlig verksamhet.
Address
Torshamnsgatan 35 1tr
Phone
+4620790282
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 379 938 | 442 049 | 417 858 | 441 322 | 476 553 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 20 434 | 23 123 | 50 161 | 40 140 | 20 610 |
| Depreciation & amort. | −4 512 | −4 901 | −5 105 | −5 407 | −4 732 |
| EBIT | 15 922 | 18 222 | 45 056 | 34 733 | 15 878 |
| Net financials | −4 403 | −6 908 | −9 444 | −9 478 | −6 610 |
| Profit before tax | 11 519 | 11 314 | 35 611 | 17 756 | 9 268 |
| Tax | −2 881 | −4 555 | −7 551 | −4 286 | −7 494 |
| Net profit | 8 638 | 6 759 | 28 060 | 13 470 | 1 774 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 135 679 | 128 222 | 134 725 | 130 912 | 144 075 |
| Equity | 76 965 | 21 724 | 49 785 | 63 255 | 65 029 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 58 713 | 106 497 | 84 940 | 67 658 | 79 046 |
| Total debt | 58 713 | 106 497 | 84 940 | 67 658 | 79 046 |
EBITDA margin
4.3%
This company
15.8%
Market median
-73% vs market
20202024
Equity ratio
45.1%
This company
38.2%
Market median
+18% vs market
20202024
Return on equity
2.7%
This company
18.4%
Market median
-85% vs market
20202024
Net profit margin
0.4%
This company
8.1%
Market median
-95% vs market
20202024
Asset turnover
3.31×
This company
1.12×
Market median
+196% vs market
20202024
Debt / equity
1.22×
This company
0.62×
Market median
-97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MR Chief Auditor | Chief Auditor | 2023 |
RT Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (2) | ||
ÅI Chief Auditor | Chief Auditor | 2022 – 2023 |
MV Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2020 | |
| Former (2) | ||
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
QIAGEN N.V.
Qiagen AB (this company)Board members of Qiagen AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mathias Rolf Forssmark | Chief Auditor | 0 companies |
| Åsa Ingegerd Malmborg | Chief Auditor | 0 companies |
| Rolf Thorbjörn Svensson | Chief Executive Officer | 0 companies |
| Miguel Vittrup Poulsen | Chief Executive Officer | 0 companies |
| Antonio Mendes Santos | Board of Directors | 0 companies |
| Roland Sackers | Deputy Board Member | 0 companies |
| Barthold Dr. Piening | Board of Directors | 0 companies |
| Peer Michael Schatz | Board of Directors | 0 companies |